While many patients with chronic myeloid leukemia are open to stopping their tyrosine kinase inhibitor, others who are eligible for discontinuation decline the opportunity. What holds them back?

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.

Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people ...

Researchers developed a computational model to optimize drug selection for chronic myelogenous leukemia (CML), tailoring ...

Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...